AusBiotech Appoints Leaders for Advocacy and Industry Voice

AusBiotech is delighted to welcome two new senior leaders to its team with both roles focused on elevating and amplifying the voice of our members as we work to accelerate the growth of Australia's biotech and medtech industry.

Karyn McIntosh has been appointed as AusBiotech's new Director Government & Policy and Emma Boscheinen as the new Director Communications.

AusBiotech CEO, Rebekah Cassidy said, "we couldn't be happier to welcome Karyn and Emma to our team. Together they bring decades of well-honed advocacy, policy, international relations, strategic communications, media, and stakeholder engagement experience to the table. They are both incredibly well regarded in their fields and are excited by the opportunity to work with us and our members as we grow the Australian ecosystem and support more Australian biotech and medtech leaders to scale up and out."

About Karyn McIntosh

Karyn is a government and public policy professional with over 15 years' experience spanning law, politics, international relations and stakeholder and patient engagement in both the public and private sectors. Working across the R&D, medical manufacturing and pharmaceutical industries, Karyn is passionate about seeing breakthrough science and innovation inform good policy and advocating for policies that support a thriving and world leading life sciences ecosystem – from bench to bedside. Prior to joining AusBiotech, Kayn was Corporate Affairs Lead at global pharmaceutical company, Sanofi, with responsibility for leading political engagement, policy contribution and patient partnerships for the pharmaceutical portfolio. She also worked for the Australian Nuclear Science and Technology Organisation, leading their government affairs function, as well as representing Australia in international fora in areas of non-proliferation, nuclear law and women in nuclear. Karyn was admitted as a Solicitor in 2007, practicing in the areas of family and property law, civil litigation and administrative law.

Karyn said, "It's a real privilege to be joining the AusBiotech team. I am looking forward to working alongside and advocating for the incredible people at the heart of Australia's life sciences ecosystem. I have always been passionate about ensuring Australia's policy landscape supports tangible outcomes for the health and well-being of Australian communities."

Karyn joins the AusBiotech team from today, 28 August 2024.

About Emma Boscheinen

Emma Boscheinen is a senior practitioner with more than ten years' experience leading strategic communications in the pharmaceutical industry. Most recently, she held a senior role in the Corporate Affairs team at Bristol Myers Squibb Australia and New Zealand (BMS). At BMS, she was responsible for driving the company's reputation through strategic media relations, executing digital media strategies, managing complex issues, and delivering national PR campaigns. She has demonstrated leadership skills in high-impact areas such as Inclusion and Diversity and led the company's first Reconciliation Action Plan. Before that, she held communications and advocacy positions in large and medium-sized companies. In 2023, she won the Health Industry Hub's Corporate Communications Individual of the Year award.

"I am thrilled to join AusBiotech as its incoming Director Communications. With Australia's life sciences sector poised for growth and opportunity, joining the team at such a critical time is a privilege. I look forward to working with members, amplifying their voices, and continuing to raise the profile of Australia's thriving life sciences industry. Ensuring our members' voices are heard within and beyond the sector will remain a top priority."

Emma joins the AusBiotech team from 30 September 2024.

/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.